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Abstract
Background: Efficacy of maintenance therapy in ulcerative colitis (UC) in the remission stage has been reported to
depend on release profile or dosing regimen of oral 5-aminosalicylic acid (5-ASA) products used. Aim of this study
is to investigate real life results in using oral 5-ASA products for maintaining mild to moderate UC patients in Japan.
Methods: Adult UC outpatients treated with oral 5-ASA products were enrolled from 379 sites in Japan between
July 2012 and July 2013, and followed for 52 weeks. Remission maintenance rate was evaluated by products and
dosages. Factors affecting recurrence were also examined.
Results: A total of 5695 UC patients were registered. Among the 4677 patients in whom remission maintenance
was observed, remission maintenance rate at week 52 was 80.2%. As for disease duration and dosage, Pentasa®
4000 mg/day in 2 divided doses was administered to 480 (21.0%) patients in remission and 341 (46.6%) patients in
active stage, and Asacol® 3600 mg/day in 3 divided doses was administered to 696 (46.4%) patients in remission
and 473 (67.3%) patients in active stage.
The remission maintenance rate at week 52 by dosage and frequency did not significantly differ between Pentasa®
Tablets at 4000 mg/day in 2 divided doses (76.5%) and Asacol® Tablets at 3600 mg/day in 3 divided doses (76.1%,
P = 0.7868).
Factors affecting the risk of relapse in UC were identified. Significantly persistent remission maintenance was noted
in patients in whom duration of remission maintenance until enrollment was 12 to <24 months or ≥24 months
relative to the reference category of <3 months (12 to <24 months: HR 0.600 [0.486–0.740], p < 0.0001];
≥24 months: HR 0.352 [0.289–0.431], p < 0.0001).
Conclusions: Efficacy of real life results in using oral 5-ASA products for maintaining mild to moderate UC patients
was favorable. Maintaining remission for 12 months or longer after induction therapy was shown to reduce
recurrence risk thereafter.
Trial registration: UMIN 000008563 (the date of registration: July 30, 2012), ClinicalTrials.gov NCT01654783
(the date of registration: July 30, 2012)
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Background
Ulcerative colitis (UC) is a diffuse non-specific inflam-
matory bowel disease of unknown cause, characterized
by erosions and ulcers in the large intestine. Since desig-
nation in 1973 as a specified disease (intractable disease)
by the Ministry of Health and Welfare (at that time) in
Japan, the patient population has been growing and
exceeded 160 thousand patients in 2013, as estimated
based on the number of medical care certificates and
registration certificates issued [1].
The medical therapy for UC involves remission induc-
tion in the active stage and remission maintenance after
induction has been achieved. The Guidelines for Treat-
ment of Ulcerative Colitis 2014 (internal medicine) [2]
recommend remission maintenance with 5-aminosalycilic
acid (5-ASA) products (oral agent, enema, suppository), as
well as immunomodulators (azathioprine, 6-MP), inflixi-
mab infusion, and adalimumab subcutaneous injection.
Among these drugs, 6-MP has not been approved UC in
Japan. For infliximab and adalimumab, scheduled main-
tenance therapy is recommended only for cases that
achieved remission induction with the drug.
In Japan, the following 5-ASA products are approved
and widely used as first-line drugs for treatment of mild to
moderate UC: Salazopyrin® (salazosulfapyridine) tablets,
approved in 1969; Salazopyrin® suppositories, in 1981; Pen-
tasa® tablets, 1996; Pentasa® enema, 2002; Asacol® tablets,
2009; Pentasa® suppositories, 2013; and Pentasa® granules,
approved in 2015. After remission induction has been
achieved, 5-ASA products are continued for remission
maintenance. 5-ASA products are superior to placebo for
maintenance therapy [3]. Regarding doses of 5-ASA prod-
ucts in remission maintenance, one study has reported
that continued use of the same dose as used for remission
induction led to long-term remission maintenance [4],
while another has reported that remission maintenance
rate and patient satisfaction with prescription differed de-
pending on the dosage and frequency [5].
Aim of this study is to investigate real life results in
using oral 5-ASA products for maintaining mild to mod-
erate UC patients in Japan. In addition, risk factors for




Among UC outpatients who visited 379 medical institu-
tions in Japan between July 2012 and July 2013, those
diagnosed with mild to moderate active-stage UC or
remission-stage UC based on the Diagnostic Criteria in
Ulcerative Colitis (revised on February 13, 2010) [6] and
receiving remission induction therapy or remission
maintenance therapy with oral 5-ASA products (Pen-
tasa® Tablets, Asacol® Tablets, Salazopyrin® Tablets, and
generics of these drugs) were included in the study. The
patients were enrolled in sequential order at site visit.
The following patients were excluded from the study:
severe/fulminant active-stage UC patients, patients under-
going total/subtotal proctocolectomy, patients compli-
cated with a malignancy, pregnant or potentially pregnant
patients; and others judged ineligible by the investigator
or subinvestigators.
Patient observation and evaluation
The efficacy for remission maintenance was evaluated
during the observation period, at enrollment, week 26,
and week 52. Patients observed for longer than 52 weeks
were included in the analysis of evaluation at week 52.
At enrollment, patients were examined for the follow-
ing demographics: age, sex, height, weight, month and
year of diagnosis, classification of disease type based on
the extent of lesion (total colitis, left-sided colitis, procti-
tis, others), classification by clinical course (first onset
type, relapse-remitting type, chronic continuous type),
smoking habit, drinking habit, employment status, and
complications. Clinical course was classified as follows:
one attack only; relapse-remitting type, in which the re-
lapse and the remission are repeated; chronic continuous
type, in which the symptoms persist for >6 months from
the onset. Drinking habit was classified as follows; No
habit; once a week and less, Habit; twice a week and
more. Smoking habit was classified as follows: No habit;
non-smoker, Habit; smoker and ex-smoker. The compli-
cations were intended for all diseases. Patients diagnosed
with UC in the remission stage at enrollment were also
examined for the duration of remission maintenance
until enrollment.
At enrollment, week 26, and week 52, patients were
evaluated using partial UCDAI (pUCDAI) consisting of
stool frequency, bloody stool, and physician’s global
assessment (PGA), which was designed using the UC
disease activity index (UCDAI) by Sutherland, et al. [7]
as reference. This was a 4-point scale from 0 to 3 (max-
imum total: 9), with higher score indicating severer
symptom. The results of endoscopy, if performed, were
also evaluated on a 4-point scale. The pUCDAI was re-
ported on the case report form. Disease stage (remission,
relapse) was judged by attending UC specialist.
If prescription of an oral 5-ASA product was changed
during the observation period, the name, dose, and fre-
quency of the drug as well as the reason for the change
were recorded. If the disease stage or prescription of an
oral 5-ASA product was changed, changes during the
observation period from enrollment through week 26
were documented in the evaluation at week 26, and
those during the observation period after week 26 were
documented in the evaluation at week 52, based on the
data in the patient’s medical record. The adherence to
Nagahori et al. BMC Gastroenterology  (2017) 17:47 Page 2 of 13
medication of oral 5-ASA products was investigated
using a visual analogue scale (VAS) of a questionnaire
on adherence to medication of oral 5-ASA products
(Additional file 1). Aim of this study is to investigate real
life results in using oral 5-ASA products for maintaining
mild to moderate UC patients in Japan. Because We did
not acquire the safety data.
Study endpoints
The primary endpoint in the present study was the per-
centage of patients who maintained remission through-
out the observation period until week 52 (remission
maintenance rate). Remission maintenance rate was cal-
culated by totaling the percentage of UC patients in the
remission stage at enrollment who maintained remission
throughout the observation period and the percentage of
UC patients in the active stage at enrollment who
achieved remission induction by remission induction
therapy and maintained remission for the rest of the ob-
servation period.
The secondary endpoints were the number of relapses
(the number of relapses per year from enrollment of
remission-stage cases or from the first remission introduc-
tion after enrollment of active-stage cases, as determined
by the person-years method), duration of remission main-
tenance (the number of days from enrollment of remission-
stage cases or from remission induction of active cases until
the first relapse or discontinuation), and drug adherence
rate.
UC patients who were in the active stage at enroll-
ment or who were in the remission stage at enrollment
but experienced relapse thereafter were examined for
post-induction dose of oral 5-ASA products to calculate
remission maintenance rate separately for patients who
received the same dose as used in remission induction
or patients who received a reduced dose. In addition,
risk factors for relapse were also investigated during the
observation period.
Statistical analysis
Ito, et al. have reported 1-year remission maintenance of
76 to 80% with oral 5-ASA products [8]. In the present
study, which was an observational study, 1-year remis-
sion maintenance rate with oral 5-ASA products was as-
sumed to be 80%. The necessary sample size to provide
at least 80% power to detect 5% difference in remission
maintenance rate as statistically significant difference at
a significance level of α = 0.05 was calculated to be at
least 906 patients per group, or at least 1812 patients for
2 groups. As the Guidelines for Treatment of Ulcerative
Colitis recommend various dosing regimens of oral 5-
ASA products in remission maintenance for UC
patients, it is expected that various dosing regimens are
actually used in clinical practice. Therefore, assuming
that 1812 patients in the 2 largest study groups account
for approximately 2/5 (40%) of the overall study popula-
tion, enrollment of 4530 patients was considered neces-
sary. Although they were expected to visit study sites
regularly, the target sample size was set at 5000, allowing
for a dropout rate of approximately 10%. Patient baseline
characteristics were expressed as actual number and per-
centage for categorical variables and as mean ± standard
deviation (SD) for continuous variables. The data of the
endpoints were expressed as mean (±SD). Comparison
of remission maintenance rate by drug group was per-
formed using Cochran-Mantel-Haenszel test [9, 10] for
the following adjustment factors: age (≤60 years vs.
≥61 years), classification by the extent of lesion, classifi-
cation by clinical course, smoking habit, concomitant
use of drugs for UC other than probiotics/cytapheresis
therapy, duration of disease, and duration of remission
maintenance until enrollment (0 for patients in the
active stage at enrollment). Note that analyses by the ex-
tent of lesion and by clinical course were conducted
after exclusion of classification by the extent of lesion
and classification by clinical course, respectively, from
adjustment factors. To identify factors affecting relapse,
the following items were analyzed by stepwise selection
in the Cox regression model: age, sex, BMI, duration of
disease, classification by the extent of lesion, classifica-
tion by clinical course, smoking habit, drinking habit,
complications, concomitant use of infliximab or adali-
mumab, concomitant use of tacrolimus, concomitant
use of an immunomodulator, concomitant use of pro-
biotics, concomitant use of a 5-ASA enema or supposi-
tory, drug adherence at enrollment, type of oral 5-ASA
products used, daily dose of oral 5-ASA products, dur-
ation of remission maintenance until enrollment (0 for
patients in the active stage at enrollment), and stool




A total of 5695 UC patients were enrolled from 379 sites
in Japan. Of these, 4155 patients were in the remission
stage, and 1540 patients were in the active stage. Of all
patients enrolled, 4677 patients were included in the ob-
servational study of remission maintenance, and 1018
patients were excluded (Fig. 1).
Baseline characteristics
The patient baseline characteristics of 5695 patients en-
rolled and 4677 patients included in the observational
study of remission maintenance are shown in Table 1.
Among the 5695 patients enrolled, oral 5-ASA products
used was Pentasa® Tablets in 3023 patients (53.1%), Asa-
col® Tablets in 2202 patients (38.7%), Salazopyrin®
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Tablets in 419 patients (7.4%), a generic of any of these
drugs in 20 patients (0.4%), combination of oral 5-ASA
drugs in 28 patients (0.5%), and not indicated in 3 pa-
tients (0.1%). Daily dose of each drug was 250 mg/day to
6000 mg/day for Pentasa® Tablets, 400 mg/day to
4800 mg/day for Asacol® Tablets, and 500 mg/day to
8000 mg/day for Salazopyrin® Tablets.
By stage/dosage, the most frequently used dose of Pen-
tasa® Tablets was >2250 mg/day in both remission stage
and active stage (937 patients in the remission stage, 520
patients in the active stage), with 4000 mg/day particu-
larly commonly used (505 patients in the remission
stage, 357 patients in the active stage). Asacol® Tablets
was administered most commonly at 3600 mg/day both
in the remission stage and active stage (741 patients in
the remission stage, 488 patients in the active stage).
Salazopyrin® Tablets was administered most commonly
at 3000 mg/day both in the remission stage and active
stage (331 patients in the remission stage, 88 patients in
the active stage) (Fig. 2).
Further analysis by stage/dosage and frequency re-
vealed that Pentasa® Tablets was most frequently admin-
istered at 4000 mg/day in 2 divided doses (480 patients
[21.0%] in the remission stage, 341 patients [46.6%] in
the active stage), and Asacol® Tablets at 3600 mg/day in
3 divided doses (696 patients [46.4%] in the remission
stage, 473 patients [67.3%] in the active stage), showing
use of a high dose regardless of disease stage.
Results of the overall patients included in the
observational study of remission maintenance
Among the 4677 patients included in the observational
study of remission maintenance, the remission mainten-
ance rate at week 52 was 80.2% (95% confidence interval
[CI]: 79.0–81.3). The remission maintenance rate at
week 52 by patients who were diagnosed within two
years was 78.4%. The time-course of cumulative remis-
sion maintenance rate is shown in Fig. 3. The number of
relapses was 0.2 ± 0.5 times/person-year, and the dur-
ation of remission maintenance was 311.6 ± 103.5 days.
Remission maintenance rates by concomitant drugs,
duration of disease
The remission maintenance rate at week 52 by drug was
82.1% for oral 5-ASA alone, 78.7% for oral 5-ASA + pro-
biotics, and 77.1% for oral 5-ASA + topical 5-ASA. The
time-course of cumulative remission maintenance rate
for oral 5-ASA alone, oral 5-ASA + probiotics, and oral
5-ASA + topical 5-ASA is shown in Fig. 3.
The remission maintenance rate at week 52 by patient
which was diagnosed within 2 years was 82.0% for oral
5-ASA alone, 73.1% for oral 5-ASA + probiotics, and
74.3% for oral 5-ASA + topical 5-ASA.
Remission maintenance rates by drugs, by dosage and
frequency, by the extent of lesion, and by clinical course
in real life
The remission maintenance rate at week 52 by drug was
81.9% for Pentasa® Tablets, 78.0% for Asacol® Tablets,
and 77.6% for Salazopyrin® Tablets, and 3-group com-
parison after adjustment for adjustment factors showed
no significant difference among the 3 groups (p = 0.1426,
Fig. 4a).
The remission maintenance rate at week 52 by dos-
age and frequency did not significantly differ between
Pentasa® Tablets at 4000 mg/day in 2 divided doses and
Asacol® Tablets at 3600 mg/day in 3 divided doses
which were bases of the case setting of the present
Enrolled UC patients n = 5,695
UC patients in the remission stage n = 4,155 UC patients in the active stage n = 1,540
Patients excluded from analysis n = 876
Reason for exclusion from analysis#1
No. of 
cases
No visits after enrollment 118
Oral 5-ASA products not administered 3
Oral 5-ASA products discontinued before week 
26
2
CRF entry error/omission 12
Change in disease stage unknown 9
#1 There is some overlap among categories
Reason for exclusion from analysis#1
No. of 
cases
Active stage continued (remission induction 
not achieved)
674
Remission induced at week 52 121
Remission induced at week 26 and no 
subsequent data available
9
No visits after enrollment 71
Oral 5-ASA products discontinued before 
week 26
1
CRF entry error/omission 4
Change in disease stage unknown 1
#1 There is some overlap among categories
Patients included in analysis
in the remission stage
n = 4,013 Patients included in analysis
in the active stage
n = 664
Patients excluded from analysis n = 142
Patients included in analysis n = 4,677
Fig. 1 Patient Disposition
Nagahori et al. BMC Gastroenterology  (2017) 17:47 Page 4 of 13
Table 1 Patient Baseline Characteristics
Item No. of enrolled patients
(n = 5, 695)a
No. of patients receiving remission
maintenance (n = 4, 677)b
No. of patients (%) No. of patients (%)
Sex Male 3188 (56.0) 2610 (55.8)
Female 2505 (44.0) 2065 (44.2)
Unknown 2 (0.0) 2 (0.0)
Age (years) <20 8 (0.1) 4 (0.1)
20–30 713 (12.5) 538 (11.5)
31–40 1327 (23.3) 1063 (22.7)
41–50 1371 (24.1) 1114 (23.8)
51–60 1010 (17.7) 869 (18.6)
61 - 70 826 (14.5) 713 (15.2)
≥71 435 (7.6) 373 (8.0)
Not indicated 5 (0.1) 3 (0.1)
BMI <18.5 609 (10.7) 485 (10.4)
18.5–<25.0 4061 (71.3) 3354 (71.7)
≥25.0 975 (17.1) 801 (17.1)
Not indicated 50 (0.9) 37 (0.8)
Disease stage Disease stage No. of patients (%) No. of patients (%)
Active stage Mild 1303 (22.9) 574 (12.3)
Moderate 236 (4.1) 89 (1.9)
Not indicated 1 (0.0) 1 (0.0)
Remission stage 4155 (73.0) 4013 (85.8)
Extent of lesion Total colitis type 2378 (41.8) 1942 (41.5)
Left-sided colitis type 1951 (34.3) 1391 (34.0)
Proctitis type 1243 (21.8) 1043 (22.3)
Other 121 (2.1) 99 (2.1)
Not indicated 2 (0.0) 2 (0.0)
Clinical course First onset type 953 (16.7) 838 (17.9)
Relapse-remitting type 3995 (70.1) 3427 (73.3)
Chronic continuous type 745 (13.1) 410 (8.8)
Not indicated 2 (0.0) 2 (0.0)
Drinking habit No 3250 (57.1) 2631 (56.3)
≤1 day/week 1201 (21.1) 992 (21.2)
2 - 5 days/week 712 (12.5) 595 (12.7)
≥6 days/week 513 (9.0) 443 (9.5)
Not indicated 19 (0.3) 16 (0.3)
Smoking habit No 4207 (73.9) 3442 (73.6)
Yes 1473 (25.9) 1222 (26.1)
Not indicated 15 (0.3) 13 (0.3)
Complications Yes 1166 (20.5) 966 (20.7)
No 4529 (79.5) 3711 (79.3)
Employment status Student 136 (2.4) 108 (2.3)
Part-time worker 645 (11.3) 534 (11.4)
Full-time worker 3242 (56.9) 2632 (56.3)
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study, or between Pentasa® Tablets at 2000 mg/day in 1
dose and Asacol® Tablets at 2400 mg/day in 3 divided
doses, regardless of use of concomitant drugs (other
than probiotics) (Fig. 4b, c).
Comparisons of the remission maintenance rate at
week 52 by the extent of lesion and by clinical course
also revealed no significant difference between Pentasa®
Tablets at 4000 mg/day in 2 divided doses and Asacol®
Tablets at 3600 mg/day in 3 divided doses, or between
Pentasa® Tablets at 2000 mg/day in 1 dose and Asacol®
Tablets at 2400 mg/day in 3 divided doses for either
comparison (Fig. 4d, e).
Remission maintenance rate by the presence or absence of
dose reduction after remission had been induced in real life
The number of cases in the active stage at enrollment that
achieved remission induction by remission induction
therapy and the number of cases in the remission stage at
enrollment that had relapse during the observation period
and then achieved remission induction by remission in-
duction therapy totaled 1373. Of these cases, dose was not
reduced after remission had been induced in 1181 cases
(86.0%), supporting the general practice of not reducing
dose immediately after remission induction. In the group
receiving reduced dose after remission had been induced
(dose reduction group) and the group receiving main-
tained dose (non-dose reduction group), the remission
maintenance rate was 83.0 and 81.8%, respectively, show-
ing almost the same values (p = 0.7823, Fig. 5).
Factors affecting relapse
The following factors were identified to affect relapse,
for patients with those factors at enrollment having a
higher subsequent risk for relapse: left-sided colitis
Table 1 Patient Baseline Characteristics (Continued)
Other 1666 (29.3) 1401 (30.0)
Not indicated 6 (0.1) 1 (0.0)
Use of oral 5-ASA agent Pentasa® 3023 (53.1) 2528 (54.1)
Asacol® 2202 (38.7) 1743 (37.3)
Salazopyrin® 419 (7.4) 368 (7.9)
Other (generic) 20 (0.4) 16 (0.3)
Concomitant use (oral products) 28 (0.5) 22 (0.5)
Not indicated 3 (0.1) 0 (0.0)
concomitant medication Yes 2669 (46.9) 2076 (44.4)
No 3026 (53.1) 2601 (55.6)
probiotics 960 (16.9) 789 (16.9)
topical 5-ASA 810 (14.2) 593 (12.7)
topical steroid 259 (4.5) 170 (3.6)
systemic steroid 401 (7.0) 275 (5.9)
immunomodulator 870 (15.3) 699 (14.9)
anti-TNF 169 (3.0) 129 (2.8)
tacrolims 52 (0.9) 26 (0.6)
cyclosporine 1 (0.0) 0 (0.0)
leukocyte apheresis 37 (0.6) 21 (0.4)
pUCDAI and score of each category
(Mean ± SD)
pUCDAI 0.9 ± 1.5 (n = 5694) 0.6 ± 1.2 (n = 4677)
Stool frequency 0.4 ± 0.7 (n = 5694) 0.3 ± 0.6 (n = 4677)
Bloody stool 0.2 ± 0.5 (n = 5695) 0.1 ± 0.4 (n = 4677)
PGA 0.3 ± 0.5 (n = 5695) 0.2 ± 0.4 (n = 4677)
Duration of disease (mean ± SD) (months) 108.2 ± 93.5 110.5 ± 95.0
(n = 5670) (n = 4658)
Duration of remission maintenance until enrollment 31.4 ± 40.3 31.6 ± 40.5
(mean ± SD) (months) (n = 4107) (n = 3958)
Drug adherence (mean ± SD) 90.5 ± 14.2% (n = 5648) 90.7 ± 13.7% (n = 4646)
a%: Percentage of a total of 5695 patients
bSubjects other than those remaining in the active stage throughout the observation period from enrollment. %: Percentage of a total of 4677 patients
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relative to the reference category of total colitis as the
extent of lesion (hazard ratio [HR] = 1.159 [1.001–1.341],
p = 0.0487); relapse-remitting type relative to the refer-
ence category of first onset type as disease stage (HR =
1.456 [1.198–1.770]; p = 0.0002); and bloody stool score
2 relative to the reference category of score 0 as symp-
tom (HR 1.721 [1.126–2.628], p = 0.0120). In contrast,
significantly persistent remission maintenance was noted
in patients in whom duration of remission maintenance
until enrollment was 12 to <24 months or ≥24 months
relative to the reference category of <3 months (12 to
<24 months: HR 0.600 [0.486–0.740], p < 0.0001];
≥24 months: HR 0.352 [0.289–0.431], p < 0.0001)
(Table 2).
Drug adherence
Drug adherence was 90.5% ± 14.2% (n = 5648) at enroll-
ment, 90.8% ± 13.8% (n = 5, 332) at week 26, and 91.0%
± 13.8% (n = 4984) at week 52, confirming extremely fa-
vorable adherence. The drug adherence by dosage and
frequency at enrollment was 91.2% ± 13.5% (n = 409) for
one dose/day, 90.8% ± 14.6% (n = 2324) for 2 divided
doses/day, 90.2% ± 14.0% (n = 2848) for 3 divided
doses/day, and 86.6% ± 14.2% (n = 65) for 4 divided
doses/day, showing favorable adherence regardless of
dosage and frequency.
Discussion
In the present study, 5695 patients were enrolled from
379 sites in Japan. It was confirmed that the distribu-
tions of the residential area classification, age, and sex of
enrolled patients were almost consistent with those of
the Report on Public Health Frequency and Services
FY2012 by the Ministry of Health, Labour and Welfare
[11]. Compared with the Results of Tabulation of Per-
sonal Health Records FY2007 [12], enrolled patients
showed a distribution by classification of clinical course
with a slightly higher proportion of the relapse-remitting
type and a similar distribution by disease type classifica-
tion based on the extent of lesion. Furthermore, as
Fig. 2 Number of Patients by Disease Stage at Enrollment and by Drug. a Daily dose of Pentasa® b Daily dose of Asacol® c Daily dose of Salazopyrin®
Fig. 3 Cumulative remission maintenance rate
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compared with the CARE study, conducted in Germany,
enrolled patients had longer duration of disease regard-
less of the classification of disease stage and higher
percentage of total colitis in disease type classification
based on the extent of lesion; however, the tendency
was generally similar [13]. Accordingly, the study
population was considered to be representative of the






Fig. 4 Remission maintenance rates. a Comparison by drug. Cochran-Mantel-Haenszel test. Adjustment factors: age (≤60 years, ≥61 years), classification
by the extent of lesion, classification by clinical course, smoking habit, concomitant use of drugs for UC other than probiotics/cytapheresis therapy,
duration of disease, duration of remission maintenance until enrollment (0 for patients in the active stage at enrollment). b Comparison between Pentasa®
Tablets at 4000 mg/day in 2 divided doses and Asacol® Tablets at 3600 mg/day in 3 divided doses. Cochran-Mantel-Haenszel test. Adjustment factors: age
(≤60 years, ≥61 years), classification by the extent of lesion, classification by clinical course, smoking habit, concomitant use of drugs for UC other than
probiotics/cytapheresis therapy, duration of disease, duration of remission maintenance until enrollment (0 for patients in the active stage at enrollment).
c Comparison between Pentasa® Tablets at 2000 mg/day in 1 dose and Asacol® Tablets 2400 mg/day in 3 divided doses. Cochran-Mantel-Haenszel test.
Adjustment factors: age (≤60 years, ≥61 years), classification by the extent of lesion, classification by clinical course, smoking habit, concomitant use of
drugs for UC other than probiotics/cytapheresis therapy, duration of disease, duration of remission maintenance until enrollment (0 for patients in the
active stage at enrollment). d Comparison by the extent of lesion. Cochran-Mantel-Haenszel test. Adjustment factors: age (≤60 years, ≥61 years),
classification by clinical course, smoking habit, concomitant use of drugs for UC other than probiotics/cytapheresis therapy, duration of disease, duration of
remission maintenance until enrollment (0 for patients in the active stage at enrollment). e Comparison by clinical course. Cochran-Mantel-Haenszel test.
Adjustment factors: age (≤60 years, ≥61 years), classification by the extent of lesion, smoking habit, concomitant use of drugs for UC other than probiotics/
cytapheresis therapy, duration of disease, duration of remission maintenance until enrollment (0 for patients in the active stage at enrollment)
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It was as follows that it was thought for reasons of
drop off treatment or follow up.
(1) No visits after enrollment: in the remission stage,
self-interruption of the treatment with remission continu-
ing and custom having occurred, in the active stage, self-
interruption by the symptom improvement, the hospital
transfer by a symptom not being improved, (2) Remission
induced at week 26 and no subsequent data available:
self-interruption by the symptom improvement, (3) Oral
5-ASA products discontinued before week 26: changing to
treatment except the oral 5-ASA product prescription.
Among 4677 patients included in the analysis popula-
tion (patients in the remission stage at enrollment and
those in the active stage at enrollment who had achieved
remission induction), remission maintenance rate at
week 52 was 80.2%. A remission maintenance rate of
oral 5-ASA alone was slightly high as a result of real life.
It was thought that these results had more oral 5-ASA
alone the calm patients with symptom.
Also, remission maintenance rate of real life, oral 5-
ASA alone, oral 5-ASA + probiotics, oral 5-ASA + topical
5-ASA were higher than the patients which were diag-
nosed within two years. It was thought to be many ratios
of patients that the activity was higher in the patients
which were as diagnosed within two years.
By drug, the remission maintenance rate was 81.9%
(n = 2520) for Pentasa®, 78.0% (n = 1755) for Asacol®
Tablets, and 77.6% (n = 370) for Salazopyrin® Tablets,
showing high values for all the drugs. The absence of
significant difference in remission maintenance rate
among the 3 groups suggests that the type of drug
hardly affects efficacy in clinical practice despite the
difference in release profile. The lack of significant dif-
ference in remission maintenance rate in the compari-
sons between Pentasa® Tablets at 2000 mg/day in one
dose and Asacol® Tablets at 2400 mg/day in 3 divided
doses, and between Pentasa® Tablets at 4000 mg/day in
2 divided doses and Asacol® Tablets at 3600 mg/day in
3 divided doses further supported the discussion above.
On the other hand, it was confirmed that patients with
remission maintained for 12 months or longer prior to
enrollment have a reduced subsequent risk for relapse
than those with remission maintained for less than
12 months. Green, et al. reported that annual relapse
rate was 35% in patients who newly achieved remission
induction after enrollment, compared with 21% in those
who had maintained remission since before enrollment
[14]. The present study also identified relationship be-
tween the duration of remission maintenance and risk
for relapse and demonstrated that treatment that enables
remission maintenance for at least 12 months leads to a
reduction in subsequent risk for relapse. This is of ex-
treme significance in that it determined the approximate
desirable duration of remission induction. The reason
that female patients tended to be relapse did not un-
known. Bitton A, et al. reported that multivariate Cox
regression analysis retained greater number of prior re-
lapses in women as predictors of shorter time to clinical
relapse. However, there was no significant effect of
medication use on the strong interaction between gen-
der (female) and number of prior relapses [15].
The results of the present study suggested that 12-month
or longer continued use of the dose that successfully in-
troduces remission would be an approach to reducing a
risk for relapse in treatment with oral 5-ASA products.
The comparison between the group receiving reduced
dose after remission had been first induced (dose reduc-
tion group) and the group receiving maintained dose
(non-dose reduction group), however, failed to show def-
inite difference in remission maintenance rate. This is ex-
plained as follows: In the present study, the duration of
observation was set at 52 weeks from the time of enroll-
ment; therefore, for example, for patients in the active
stage at enrollment, the duration required for remission
induction was to be included in the duration of observa-
tion, resulting in the duration of remission maintenance
shorter than 52 weeks. Nevertheless, if in the remission
stage at week 52, the cases were judged to have main-
tained remission, resulting in a failure to demonstrate the
difference between the presence and absence of dose re-
duction after remission had been induced. And we did not
conduct sub analysis of endoscopic evaluation. A future
long-term observational study starting from the time of
remission induction involving endoscopic evaluation will
reveal a difference in remission maintenance rate between
the presence and absence of dose reduction.
Fig. 5 Remission Maintenance Rate by the Presence or Absence
of Dose Reduction after Remission has been Induced. Cochran-
Mantel-Haenszel test. Adjustment factors: age (≤60 years,
≥61 years), classification by the extent of lesion, classification by
clinical course, smoking habit, concomitant use of drugs for UC
other than probiotics/cytaphresis therapy, duration of disease,
duration of remission maintenance until enrollment (0 for patients
in the active stage at enrollment)
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Table 2 Factors Affecting Relapse

















Age (years) <20 4
20–30 538 0.778 0.109–5.563 p = 0.8028
31–40 1063 0.611 0.086–4.358 p = 0.6233
41–50 1114 0.545 0.076–3.887 p = 0.5450
51–60 869 0.491 0.069–3.504 p = 0.4777
61–70 713 0.414 0.058–2.966 p = 0.3802
≥71 373 0.336 0.046–2.435 p = 0.2807
Sex Male 2610
Female 2065 1.165 1.024–1.326 p = 0.0201 1.126 0.988–1.282 p = 0.0744
BMI <18.5 485
18.5–<25.0 3354 0.883 0.718–1.087 p = 0.2411




12–<60 1424 0.808 0.631–1.034 p = 0.0900
60–<120 1238 0.738 0.573–0.950 p = 0.0186






1591 1.204 1.042–1.393 p = 0.0121 1.159 1.001–1.341 p = 0.0487
Proctitis type 1043 0.910 0.762–1.086 p = 0.2937 0.957 0.800–1.144 p = 0.6271
Other 99 0.773 0.461–1.295 p = 0.3282 0.858 0.512–1.439 p = 0.5618
Classification by linical
course
First onset type 838
Relapse-remitting
type
3427 1.608 1.325–1.952 p < 0.0001 1.456 1.198–1.770 p = 0.0002
Chronic continuous
type
410 1.379 1.024–1.859 p = 0.0344 1.133 0.837–1.534 p = 0.4175
Smoking habit Yes 1222
No 3442 1.036 0.893–1.201 p = 0.6421
Drinking habit No 2631
≤1 day/week 992 1.060 0.900–1.247 p = 0.4865
2–5 days/week 595 1.058 0.867–1.289 p = 0.5797
≥6 days/week 443 1.050 0.842–1.309 p = 0.6670
Complications Yes 965
No 3712 1.094 0.930–1.286 p = 0.2788
Employment status Student 108
Part-time worker 534 0.751 0.497–1.135 p = 0.1740
Full-time worker 2632 0.705 0.482–1.031 p = 0.0714








No 4651 0.722 0.300–1.738 p = 0.4674
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The study of possible relationship between relapse and
adherence in remission-stage UC patients by Kane, et al.
reported that all of the patients with relapse at month 6
of follow-up (12%) and 68% of patients with relapse at
month 12 months were non-adherent patients (adher-
ence < 80%) [16]. In addition, Kawakami, et al. reported
twice higher risk for relapse in non-adherent patients
than in adherent patients [17], suggesting relationship
between reduced adherence and increased risk for re-
lapse. Furthermore, as for the reasons for drug adher-
ence, Kane, et al. cited skipped doses (50%), the large
number of tablets (30%), and no need felt (20%) [16],
and Hawthorne, et al. reported involvement of frequent
dosing (3 times daily) [18]. Meanwhile, the survey by
Kawakami, et al. reported extremely high adherence in
Japanese UC patients [17], and the study by Watanabe, et
al. did not provide evidence for the effect of the number of
doses [19]. As the reason for high adherence in Japanese
patients, Japanese temperament and direct consultation
with IBD expert as well as lack of financial concerns thanks
to financial support system for UC patients (Research on
Measures for Intractable Diseases) have been cited [17].
The present study confirmed high remission mainten-
ance rate at week 52, which is considered to be








No 3888 0.919 0.777–1.086 p = 0.3208
Concomitant use of 5-ASA
enema/suppository
Yes 594




≥80% 3941 1.132 0.939–1.364 p = 0.1926
Type of oral 5-ASA products
at enrollment
Pentasa® Tablets 2528
Asacol® Tablets 1744 1.301 1.136–1.490 p = 0.0001
Salazopyrin® Tablets 368 1.273 1.007–1.608 p = 0.0435
Other (generic) 16 0.000 0.000 > 999.999 p = 0.9351
Concomitant use
(oral products)
22 1.092 0.408–2.921 p = 0.8615
Daily dose of oral 5-ASA
products at enrollment (mg)
<1500 287
≥1500–<2500 1982 1.190 0.864–1.640 p = 0.2874





≥3–<12 1013 0.854 0.721–1.011 p = 0.0662 0.928 0.772–1.115 p = 0.4236
≥12–<24 824 0.542 0.445–0.661 p < 0.0001 0.600 0.486–0.740 p < 0.0001
≥24 1703 0.316 0.263–0.380 p < 0.0001 0.352 0.289–0.431 p < 0.0001
Stool frequency score at
enrollment
0 3539
1 874 1.331 1.132–1.564 p = 0.0005 1.129 0.952–1.339 p = 0.1642
2 195 1.788 1.351–2.366 p < 0.0001 1.334 0.986–1.806 p = 0.0618
3 69 0.882 0.439–1.772 p = 0.7243 0.618 0.303–1.262 p = 0.1864
Bloody stool score at
enrollment
0 4159
1 413 1.693 1.371–2.090 p < 0.0001 1.249 0.988–1.578 p = 0.0631
2 98 2.712 1.845–3.987 p < 0.0001 1.721 1.126–2.628 p = 0.0120
3 7 0.000 0.000–>999.999 p = 0.9476 0.000 0.000–>999.999 p = 0.9446
PGA score at enrollment 0 3830
1 770 1.564 1.324–1.847 p < 0.0001
2 76 1.212 0.668–2.200 p = 0.5275
3 1 0.001 0.000–>999.999 p = 0.9535
#1 Factors affecting relapse in terms of the duration until relapse were investigated using a Cox regression model (multivariate) with the items having p < 0.05 in
univariate analysis as explanatory variables
#2 Duration of remission maintenance was counted as 0 month for the patients in active stage at enrollment
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attributable to Japanese-unique favorable drug adherence.
It would therefore be fundamental to UC treatment to
fully convince patients of the importance of drug adher-
ence for reduction in relapse risk even in the asymptom-
atic remission stage, thereby pursuing enhancement of
adherence.
The data of the concomitant medication describe the
drug which they used together at enrollment.
Conclusions
The present study demonstrated consistently high drug ad-
herence and favorable remission-maintaining effect of real
life results in using oral 5-ASA products for maintaining
mild to moderate UC patients in Japan. This study also sug-
gested the importance of continuing remission maintenance
for at least 12 months for a reduction in a risk for relapse.
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